Mallinckrodt is partnering with admedicum

Lung Cancer Europe shared on X:

“Mallinckrodt, a patient-focused pharmaceutical company, is partnering with admedicum, a patient engagement expert, to launch a collaborative project focused on immune-related colitis, a complication of ICI treatment.

As Mallinckrodt is developing a potential new treatment for immune-related colitis, this project aims to involve patients early on by forming a focus group to discuss:

• symptoms and burden of immune-related colitis
• unmet needs of patients experiencing this complication.

The project is seeking:

• Melanoma or lung cancer patients who experienced or are experiencing colitis as a side effect of ICI treatment and have received treatment for it
• Patient reps from advocacy groups with experience/knowledge of immune-related colitis in ICI patients

The first virtual focus group meeting is planned for late June/early July 2024 and will last 3-4 hours. Participants will receive preparation materials beforehand. Subsequent meetings and tasks will be discussed during the first meeting, with participation optional.

Compensation will be provided for attending meetings and any preparatory/follow-up activities.
If interested in taking part of the project or need more information, please contact Razak Ellafi at [email protected].”

Source: Lung Cancer Europe/X